Introduction {#s1}
============

Stress is a complex process involving individual resources, vulnerabilities as well as the environment ([@B1]). Psychological, behavioral and physiological adaptations to survival requirements are necessary for an individual\'s capacity to adapt ([@B2]--[@B4]). Chronic exposure to stressful stimuli, is referred to as *allostatic load* (AL), and results in "wear and tear" of the adaptive regulatory systems resulting in biological alterations that weaken stress adaptive processes and increase disease susceptibility ([@B2], [@B3]). Chronic dietary imbalances, for example as observed in western diets rich in fats and refined sugars that lead to excessive weight gain, may affect physiological performance promoting chronic low-inflammation that is detrimental for both the physical and mental status ([@B5]--[@B7]). The consequential increase in pro-inflammatory cytokines, such as IL-6, leads to increased hypothalamic-pituitary-adrenal (HPA-) axis activity ([@B8]) and promotes chronic stress. In this study, we measured AL scores in a Caucasian pediatric population, in order to define a correlation between cumulative biological dysregulation and excess weight.

Patients and Methods {#s2}
====================

Patients
--------

We consecutively enrolled 164 Caucasian children and adolescents (79 females and 85 males) aged 11.89 ± 3.89 y (range 2.6--18.0 y). The subjects were referred to our institution for auxological evaluation or obesity by their general practitioner or by their primary care pediatric consultant, between October 2017 and March 2018.

After receiving information on the nature of the study, written informed consent was obtained from the parents of the patients or the participants. Participants were excluded from the study if they had concurrent chronic or acute illnesses, any known secondary syndromes with or without obesity, or were on any medications. According to body mass index (BMI) cutoffs and age-sex percentiles ([@B9]) subjects were classified as normal for weight: BMI \< 75th percentile, overweight: BMI 75--95th percentile or obese: BMI \>95th percentile.

Methods
-------

### Allostatic Load Definition

We used 16 biomarkers to create an AL summary score. In the original definition of the AL index, ([@B2]) biomarkers of cardiovascular, metabolic, and endocrine stress regulatory systems were included. Acknowledging the important role that inflammation plays in the response to stress and many diseases, inflammation biomarkers were added at a later time ([@B3]). As previously reported ([@B10]), since the AL biomarker panel is not univocal ([@B11]), we included markers for cardiovascular, metabolic, inflammatory and stress hormone status ([@B11]). As markers of cardiovascular and metabolic activity, in addition to BMI, we included parameters that are usually considered in metabolic syndromes, such as, waist circumference (WC), waist to height ratio (WHtR), blood pressure, fasting lipid and blood glucose levels, insulin resistance, transaminases and homocysteine levels. The latter is recognized as an independent risk factor for cardiovascular disease ([@B12]). As inflammatory markers we included calprotectin ([@B13]), IL-6 and PCR; while the serum cortisol level was measured as a marker of stress.

As previously described ([@B10]) for each biomarker, a dichotomous variable was constructed in which 0 and 1, respectively, correlated with values under the clinical cutoffs for age and gender and those in the pathological clinical range. Risk factors were summed to calculate a total AL score and the population median for the sum of the dysregulated components in our sample was 4. All patients who scored \<4 were considered low AL and vice versa for all the others. As previously mentioned ([@B10]) we used this dichotomous scoring system to achieve a well-matched sample size and consequently obtained more statistical power.

### Auxological Parameter Evaluation

In all patients, weight, height, waist circumference (WC), pubertal stage according to Marshall and Tanner ([@B14], [@B15]) and blood pressure were measured. BMI and the waist-to-height ratio (W/HtR) were also calculated. Weight, height, BMI, waist circumference and blood pressure were measured as previously reported ([@B13]). A BMI cut-off above the 75th percentile, indicative of an overweight status or obesity, was considered pathological; WC was considered pathological when \>95th percentile for age and sex ([@B16]). Abdominal obesity was defined with a W/HtR \>0.5 ([@B17]). Hypertension was defined for SBP or DBP as equal to or above the 95th percentile for age and sex ([@B18]).

### Metabolic, Hormonal, and Inflammatory Parameters

Metabolic and hormonal parameters included fasting blood glucose (FBG), total cholesterol, high-density lipoprotein (HDL) cholesterol; triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transferase (GGT), homocysteine, insulin and cortisol levels. The formula: insulin resistance = (fasting plasma insulin in mUI/L × fasting plasma glucose in mmol/L/22.5) was used to calculate the homeostasis model assessment for insulin resistance (HOMA-IR).

Elevated FBG was defined with values exceeding 100 mg/dl and impaired insulin sensitivity (ISI) with an HOMA-IR exceeding the 97.5th percentile for age and sex ([@B19]). Lipid fasting levels were considered pathological for total-cholesterol (TC) and TG values \>95th percentile and an HDL cholesterol level \<5th percentile for age and sex ([@B20]). Pathological ALT (normal value 11--39 mU/ml) and AST (normal value 11--34 mU/ml) and/or GGT (normal value 11--53 mU/ml) levels identified subjects with abnormal hepatic function.

Fasting blood glucose, insulin, total cholesterol, HDL, TG, AST, ALT, GGT, and PCR were measured with clinical chemistry methods using the Advia XPT (Siemens Healthcare). Morning serum cortisol was measured using the chemiluminescent enzyme immunoassay Immulite (Siemens Healthcare; intra- and inter-assay precision were 5.2 and 6.1%, respectively). Plasma homocysteine levels were measured with a competitive immunoassay using direct, chemiluminescent technology (Advia Centaur, Siemens Healthcare; intra- and inter-assay precision were 3.7 and 4.7%, respectively). Serum IL-6 was titered using an enzyme-linked immunosorbent assay kit (R and D Systems Minneapolis; range 0--12.5 pg/ml; intra- and inter-assay precision were 2.6 and 4.5%, respectively). Serum calprotectin was measured with a commercial ELISA assay (intra- and inter-assay precision were 8.0 and 9.0%, respectively) as previously described ([@B13]).

Statistical Analysis
--------------------

The Shapiro-Wilk test was used to determine normal distributions of quantitative variables and the results are reported as the mean and standard deviation (SD). Gender and pubertal stages were considered as qualitative variables and summarized as counts and percentages and compared between groups with the chi-square test. Associations between dichotomous AL (high vs. low) and clinical, metabolic and hormonal data were evaluated by the Student *t*-test for independent samples. The non-parametric test for trends across ordered groups was used to assess the effect of obesity on cumulative biological dysregulation. All tests were two-sided and a *p*-value \< 0.05 was considered statistically significant. The STATA statistical package was used to perform data analyses (release 15 January 2017, Stata Corporation, College Station, Texas, USA).

Results {#s3}
=======

Based on the BMI percentile threshold, 49 of the 164 (29.88%) enrolled patients were normal for weight and 115 (70.12%) were overweight or obese. [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} show the biomarker distributions utilized for the AL summary score, and the number of dysregulated values used to generate the score.

###### 

Parameter distributions used to create the allostatic load (AL) summary score.

  **Parameters**                                                                              **Absent**     **Present**
  ------------------------------------------------------------------------------------------- -------------- --------------
  Body mass index \> 75th percentile                                                          49 (29.88%)    115 (70.12%)
  Waist circumference \> 95th percentile                                                      57 (34.76%)    107(65.24%)
  Waist to height ratio \> 0.5                                                                68 (41.46%)    96 (58.54%)
  Systolic blood pressure ≥ 95th percentile                                                   144 (87.8%)    20 (12.2%)
  Diastolic blood pressure \> 95th percentile                                                 153 (93.29%)   11 (6.71%)
  High density lipoprotein (HDL) cholesterol \< 5th percentile                                113 (81.09%)   31 (18.91%)
  Total cholesterol \> 95th percentile                                                        149 (90.85%)   15 (9.15%)
  Triglycerides \> 95th percentile                                                            152 (92.68%)   12 (7.32%)
  Fasting blood glucose \> 100 mg/dl                                                          161 (98.17%)   3 (1.83%)
  HOMA-IR \> 95th percentile                                                                  136 (82.92)    28 (17.18%)
  Pathological ALT (nv 11--39 mU/ml) and AST (nv 11--34 mU/ml) and/or GGT (nv 11--53 mU/ml)   162 (98.78%)   2 (1.22%)
  Homocysteine (nv 5--13.9 μmol /L)                                                           132 (80.48%)   32 (19.52%)
  PCR \> 0.5 mg/L                                                                             145 (88.41%)   19 (11.59%)
  Pathological IL-6 (nv 0--12.5 pg/ml)                                                        160 (97.56%)   4 (2.44%)
  Pathological calprotectin (nv 0.3--1.6 μg/ml)                                               75 (45.73%)    89 (54.27%)
  Elevated morning cortisol level (nv 4.3--22.4 μg /ml)                                       163 (99.39%)   1 (0.61%)

*nv, normal value; HOMA-IR, homeostasis model assessment for insulin resistance*.

###### 

Number of dysregulated components used to create the allostatic load summary score.

  **Number of AL parameters**   **Percentage of patients (%)**   **Cumulative percentage of patients (%)**
  ----------------------------- -------------------------------- -------------------------------------------
  0                             14.02                            14.02
  1                             12.80                            26.83
  2                             4.27                             31.10
  3                             15.24                            46.34
  4                             15.24                            61.59
  5                             17.68                            79.27
  6                             11.59                            90.85
  7                             5.49                             96.34
  8                             1.22                             97.56
  9                             1.83                             99.39
  10                            0.61                             100

A high AL score was observed in 88/164 subjects (53.65%), without significant differences between genders (*p* = 0.07) or pubertal status (*p* = 0.10). In [Table 3](#T3){ref-type="table"}, we report the correlations between AL, clinical data and metabolic/hormonal parameters. Subjects with a significantly higher BMI (*p* \< 0.001), WC and WC/HtR (*p* \< 0.001), triglycerides (*p* = 0.002), fasting blood glucose (*p* = 0.03), GGT (*p* = 0.01), PCR (*p* = 0.01), calprotectin (*p* \< 0.01) insulin resistance (*p* \< 0.001), systolic (*p* \< 0.0019), and diastolic blood pressure (*p* = 0.001) values as well as lower HDL cholesterol (*p* = 0.002) levels had a higher AL score.

###### 

Correlation between allostatic load (AL), clinical data, and biochemical/hormonal parameters.

  **Parameters**                                            **Low AL (\<4)**   **High AL (≥4)**    ***p*\_value**
  --------------------------------------------------------- ------------------ ------------------- ----------------
  Height (cm)                                               146.59 ± 22.82     150.58 ± 15.47      0.18
  Weight (Kg)                                               45.22 ± 17.02      59.92 ± 17.65       \<0.001
  Body Mass Index (kg/m^2^)                                 21.23 ± 11.88      25.8 ± 3.88         \<0.001
  Waist circumference (cm)                                  72.47 ± 10.78      84.98 ± 9.71        \<0.001
  Waist to height ratio \> 0.5                              0.34 ± 0.04        0.55 ± 0.52         \<0.001
  **Pubertal status[^\*^](#TN1){ref-type="table-fn"}**                                             
     Tanner stage 1                                         30 (39.47)         25 (28.41)          0.10
     Tanner stages 2--3                                     40 (52.63)         55 (62.50)          
     Tanner stages 4--5                                     6 (7.80)           8 (9.09)            
  Systolic blood pressure (mmHg)                            106.54 ± 9.84      112.82 ± 10.15      \<0.001
  Diastolic blood pressure (mmHg)                           66.53 ± 8.26       70.57 ± 8.04        0.001
  High density lipoprotein cholesterol (mg/dL)              55.73 ± 11.32      49.61 ± 11.02       0.002
  Total cholesterol (mg/dL)                                 152.87 ± 22.95     160.17 ± 29.55      0.14
  Triglycerides (mg/dL)                                     60.04 ± 29.2       80.98 ± 41.8        0.002
  Fasting blood glucose (mg/dL)                             72.89 ± 10.57      76.71 ± 2.04        0.03
  HOMA-IR                                                   1.46 ± 1.13        2.57 ± 1.96         \<0.001
  Aspartate Aminotransferase (mU/ml)                        23.08 ± 5.45       23.33 ± 13.26       0.9
  Alanine Aminotransferase (mU/ml)                          14.84 ± 5.36       17.56 ± 9.16        0.06
  Gamma-Glutamyl Transferase (mU/ml)                        11.83 ± 4.64       14.58 ± 6.34        0.01
  Homocysteine (μmol /L)                                    12.68 ± 7.52       13.11 ± 3.14        0.67
  PCR (mg/L)[^\*\*^](#TN2){ref-type="table-fn"}             0.04 (0.02--0.1)   0.16 (0.03--0.48)   0.01
  IL-6 (pg/ml)[^\*\*^](#TN2){ref-type="table-fn"}           1.97 (0.8--5.7)    2.83 (1.51--5.77)   0.23
  Calprotectin (μg/ml)[^\*\*^](#TN2){ref-type="table-fn"}   1.1 (0.8--1.9)     2.6 (1.7--4.3)      \<0.001
  Cortisol (μg/ml)                                          8.20 ± 3.97        8.85 ± 4.89         0.5

*AL, allostatic load*.

*Data are expressed as the number of patients (percentage)*.

*Data are expressed as the median (interquartile range)*.

A significant correlation between high AL score and excess weight was observed (87/88 of patients with pathological BMI had a high AL score vs. 1/49 in normal weight subjects *p* \< 0.001). It was also noted that an increasing BMI correlated with increased cumulative biological dysregulation (*p* \< 0.001).

Discussion {#s4}
==========

In our pediatric population, we observed a significant correlation between high AL and overweight/obesity status and an altered cardio-metabolic profile. The cumulative biological dysregulation rose in the higher BMI categories. AL may be considered a significant factor correlated with increased morbidity in overweight/obese children.

Cumulative biological system dysregulation has been closely linked to AL ([@B21]) and has been shown to be associated with a poor health status, thus representing a key physiological impairment factor in the prodromal stages of disease ([@B22]). We detected a correlation between high AL and overlapping metabolic syndrome (MetS) parameters, such as abdominal obesity, high triglyceride levels, insulin resistance and hypertension, confirming our previous results showing a significant MetS increase with increased obesity severity in children ([@B23])^.^ Therefore, these results suggest that AL may forecast important clinical consequences including cardiovascular events and metabolic disease, as well as increased mortality ([@B2], [@B3]).

In the children and adolescents, high AL scores correlated with excess weight and increases in the BMI categories. As reported by Foss et al. ([@B8]), obesity represents a disruption of homeostasis and may be considered a potential physiological stress inducer. While it seems evident that stress induces obesity, the reverse is not well-documented. Our data support that this hypothesis should be seriously considered at the pediatric age, where stress experience is limited compared to data reported on adults. Chronic low-grade activation of the inflammatory system is a common feature of obesity and is associated with increased secretion of pro-inflammatory cytokine, such as IL-1, IL-6 and tumor necrosis factor, that trigger stimulation of HPA axis by the adipocytes, thereby increasing cortisol release in order to limit the inflammation reaction ([@B24]).

Another feature of obesity is increased leptin secretion ([@B25], [@B26]) that appears to be functionally connected with the HPA axis in humans ([@B27], [@B28]). Hyperleptinemia, which is commonly observed in obesity, can also play a role in the stress reaction.

In our population, we also detected a correlation between high AL and calprotectin levels, which has previously been associated with obesity-related chronic low-grade inflammation in children ([@B13]). The role of this molecule on the risk of developing comorbid inflammatory conditions, should be considered.

Finally, food quality and the amount of energy consumed in relation to daily recommended requirements are key determinants of the effects that contribute to chronic disease. Dietary patterns have been associated with higher AL scores ([@B29]), indicating the negative impact of refined and simple sugars as well as saturated and trans fatty acids in long term causes of chronic degenerative diseases ([@B30], [@B31]).

We acknowledge that the study has humble limitations starting from the relatively small sample size, which could have limited the analysis. Therefore, future studies with larger cohorts are mandatory. Additionally, even though our observational study revealed a higher cumulative biological dysregulation in patients with excessive weight increases, this does not prove causality and it is difficult to determine whether AL is a cause or consequence of obesity. In this pediatric population, longitudinal studies would be useful to define the impact of cumulative biological dysregulation on health. Finally, we evaluated a cohort of children in which several stressors may have simultaneously affected AL scores, including unhealthy lifestyle, chronic low-grade inflammation and hormonal dysregulation. Further research aimed at single stress parameter analysis is necessary to confirm the relationships between excess weight and cumulative biological dysregulation.

In conclusion, we describe a correlation between cumulative biological dysregulation and excess weight in children and adolescents, suggesting that AL could be a useful index of health risk in the pediatric population offering a valuable measure to predict complications in obese children and promote early tailored interventions to enhance their quality of life.
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